DLC1 is a candidate tumor suppressor gene recently isolated from human hepatocellular carcinoma (HCC). Structurally, DLC1 protein contains a conserved RhoGAP domain, which has been thought to regulate the activity of Rho family proteins. Previous studies indicated that DLC1 was frequently inactivated in cancer cells. In the present study, we aimed to characterize the tumor suppressor roles of DLC1 in HCC. We demonstrated that DLC1 significantly 
Introduction
Hepatocellular carcinoma (HCC) is the fifth commonest cancer worldwide and is the second leading fatal cancer in Southeast Asia and Hong Kong. Etiologically, HCC is closely associated with chronic hepatitis B and C virus infection, cirrhosis and aflatoxin B1 intake (1).
However, the molecular mechanisms leading to the development and progression of HCC remain unclear. In HCC, deletions of chromosomal materials are common and of a non-random pattern, with recurrent deletions on chromosomes 1p, 4q, 8p, 13q, 16q and 17p. These strongly suggest that putative tumor suppressor genes may be located in these chromosome arms (2-7).
Recently, a candidate tumor suppressor gene, namely frequently deleted in liver cancer (DLC1), was identified in primary HCC sample (8) and mapped to 8p21. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , where chromosomal deletion is particularly common in human cancers (2, (9) (10) (11) . DLC1 mRNA encodes a protein with 1,091 amino acid residues and is ubiquitously expressed in human tissues (8). The amino acid sequence of DLC1 shares 86% homology with rat p122RhoGAP and this strongly suggests that DLC1 is a p122RhoGAP human ortholog. p122RhoGAP was first identified as a phospholipase C-δ1 binding protein in a rat brain expression library screening (12) .
Structurally, both p122RhoGAP and DLC1 contain three conserved functional domains, namely SAM (sterile alpha motif), RhoGAP (GTPase activating protein for Rho family protein) and START (steroidogenic acute regulatory related lipid transfer) domains (13, 14) . Proteins 4 containing a RhoGAP domain usually function to catalyze the hydrolysis of GTP that is bound to Rho family proteins. When the bound GTP is hydrolyzed to GDP, Rho proteins return to the inactive basal state. Thus, RhoGAPs negatively regulate Rho-mediated cellular processes, such as actin cytoskeleton organization, gene expression, and cell-cycle progression (15, 16) .
Evidence has shown that hyperactivation of Rho proteins are oncogenic (17) (18) (19) (20) . Clinically, Rho proteins were found to be overexpressed in different human cancers and overexpression of Rho proteins was associated with more aggressive tumor behavior (21, 22) . Several members of the RhoGAP family have been suggested to possess potential tumor suppressor function. For instance, anti-tumor function of p190RhoGAP has been demonstrated by in vitro studies.
Overexpression of antisense p190RhoGAP RNA is able to transform normal NIH3T3 fibroblasts. In contrast, overexpression of the wild-type p190RhoGAP domain can suppress v-Ha-Ras-induced transformation (23) . Therefore, it is logical to hypothesize that DLC1 might have tumor suppressor functions by negatively regulating tumor cell growth or tumor progression through down-regulation of oncogenic activity of Rho family proteins.
In this study, we demonstrated that DLC1 reduced the proliferation rate, anchorageindependent growth ability, and in vivo tumorigenicity of HCC cells. Stable expression of DLC1 also significantly suppressed the motility and invasiveness of HCC cells. Furthermore,
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DLC1 inhibited Rho dependent stress-fiber formation in fibroblasts and HCC cells, and this Rho inhibitory function was essential for the DLC1-mediated growth inhibition in HCC cells.
Thus, our findings support the hypothesis that DLC1 is a RhoGAP antagonizing the oncogenic activity of Rho proteins and serves as a tumor suppressor gene in human HCC.
Materials and Methods

Cell lines and plasmid construction
Human HCC cell lines, SMMC-7721 and BEL7402, which lack DLC1 expression, were obtained from Shanghai Institute of Cell Biology (14, 24) . The murine fibroblast cell line Swiss-3T3 was obtained form American Tissue Culture Collection (ATCC). The rodent fibroblast cell line Rat 6 was kindly provided by Dr. W.W. Hsiao (25) . SMMC-7721 and BEL7402 were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% (vol/vol) fetal bovine serum (FBS) and antibiotics. Swiss-3T3 and Rat 6 cells were cultured in DMEM supplemented with 10% (vol/vol) calf serum (CS) and antibiotics at 37˚C in a humidified incubator with 5% CO 2 .
Plasmid construction
A 3.5-kb fragment of full-length coding sequence of the DLC1 gene was amplified from normal liver tissue and cloned into pcDNA3.1(-) vector (26) . Truncated fragments were subcloned into eukaryotic expression vector, pCS2+MT, of Myc-tagged protein as follows: 
Mutagenesis
A DLC1 fragment (1-804 a.a) was released from pcDNA3.1/DLC1 plasmid by EcoRI digestion and subcloned into pBluescript II SK (+) vector. The site-specific mutation of K714E was introduced into DLC1 cDNA by PCR mutagenesis with two consecutive PCR amplifications.
For the first PCR amplification, PCR fragments contain DLC1-K714E mutation was generated from pSK+/DLC1 (1-804 a.a.) with two set of PCR primers: 5'-GGA TGG ATG AGG AGA AGC TG -3' (set 1, forward), 5'-GAT CTC GAA AAT ACT GCT CCA -3'(set 1, reverse), 5'-TGC TGG AGC AGT ATT TTC GAG -3' (set 2, forward) and 5'-TAA TAC GAC TCA CTA TAG GG -3' (set 2, reverse). Subsequently, an aliquot of the first PCR products were used as templates for the second PCR, which was designed to amplify the full-length insert with the desired mutation in the DLC1 cDNA with the set 1 forward primer and set 2 reverse primer that have been used in the first PCR amplification. The final amplified product was excised and gel-purified. The NocI/BamHI fragment of DLC1 cDNA in pSK+/DLC1 (1-804 a.a) plasmid was then replaced by this PCR amplified fragment. The full length DLC1-K714E mutant was generated by releasing the DLC1-K714E fragment (1-804 a.a) from pSK+/DLC1 K714E 7 plasmids by EcoRI digestion and subcloned into pCS2+MT/DLC1 (805-1091 a.a.) plasmid, which was then verified by DNA sequencing.
Establishment of DLC1 stably expressing cells
Two µg of pcDNA3.1(-)/DLC1 plasmid was transfected into SMMC-7721 cells with FuGENE 6 Transfection Reagent as described by the manufacturer (Roche Molecular Biochemicals, Indianapolis, IN). After 24 hours, the transfected cells were trypsinized and splitted onto 100 mm culture dish at a density of 1 × 10 4 /dish. Transfected cells were selected for 2 weeks in culture medium containing 0.75 mg/ml G418 (Invitrogen, Carlsbad, CA). Single G418-resistant clones were isolated from the culture dish using a Cloning cylinder (Bellco Biotechnology, Vineland, NJ). The expression of DLC1 was determined by RT-PCR and Northern blotting as described previously (14) .
Cell proliferation assay
Cells (2.5 × 10 4 ) were plated in each well of 12-well culture plates containing 1 ml DMEM medium supplemented with 10% FBS or 0.5% FBS. Cells were harvested at 24-hour intervals for 7 days. Cell numbers were counted by trypan blue exclusion assay with hematocytometer.
The doubling time of proliferating cells was determined by nonlinear regression (exponential growth) model using GraphPad Prism version 3.00 (GraphPad Software, San Diego CA)
Anchorage-independent growth assay in soft-agar
Five ml of 0.5% agarose culture medium containing 10% FBS was used to coat the bottom of each of the wells of the 6-well culture plates. After hardening, 1 × 10 4 cells were suspended in 2 ml of 0.3% agarose culture medium containing 10% FBS warmed at 40°C and plated onto the bottom layer. The cell solution was allowed to set for 30 minutes at room temperature before moving into the 37°C CO 2 incubator. Colonies (≥10 cells) formed in the soft agarose culture were counted and photographed two weeks after inoculation.
Cell motility assays
For cell motility assay, 8 × 10 5 cells were seeded onto 60-mm dishes and grown for 24 hours.
Cells were treated with 10 µg/ml mitomycin C (Sigma) for 3 hours prior to the wounding. A 
Colony suppression assay
Two × 10 5 cells were seeded onto 35 mm dish one day before transfection. Two µg each of the various pCS2+MT/DLC1 constructs or the pCS2+MT empty vector were co-transfected with 0.2 µg pBABE-puro puromycin selection vector into the cells using FuGENE 6 Transfection Reagent (Roche Molecular Biochemicals). After 24 hours, cells were seeded onto 10 cm culture dishes in 1:5 dilution and grown in culture medium containing 0.6 µg/ml puromycin (Sigma) for 2 weeks. The puromycin-resistant colonies were fixed with 3.7% formaldehyde, and the colony formation efficiency was examined by Giemsa staining (Sigma).
Results
DLC1 inhibited cell proliferation, anchorage-independent growth and tumorigenicity of HCC cells
We have previously demonstrated that ectopic overexpression of DLC1 cDNA can suppress cancer cell growth in colony suppression assay (26) . In order to further characterize the tumor suppressor function of DLC1 in HCC, in this study, we established a cellular model in which 
DLC1 suppressed cell motility and invasiveness of HCC cells
To test whether DLC1 affects the motility of HCC cells, wound healing assay was performed on SMMC-7721 and SMMC-7721/DLC1 cells in the absence or presence of a cell division inhibitor, mitomycin C. Our results showed that the motility of DLC1 stably expressing cells was significantly reduced. Similar results were also obtained when the cells were pretreated with mitomycin C, which indicated that the reduction of cell motility in DLC1 expressing cells was not due to the difference in proliferation rate ( Figure 3A) . Consistently, the cell motility of SMMC-7721/DLC1 was significantly reduced in cell motility assay using invasion chamber without ECM coating, and this confirmed that expression of DLC1 inhibited cell motility
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(Supplementary Figure 1) . Furthermore, we asked whether DLC1 could suppress the invasiveness of HCC cells. To this end, we performed in vitro cell invasion assay using invasion chamber coated with an ECM layer (27) . In sharp contrast with the parental SMMC-7721 cells, the number of invasive cells was dramatically reduced in DLC1 stably expressing cells ( Figure 3B ). Thus, our results clearly demonstrated that DLC1 suppressed the cell motility and invasiveness of HCC cells.
Expression of DLC1 inhibited Rho-mediated stress fiber formation
The existence of RhoGAP domain on DLC1 protein strongly suggests that DLC1 may function were remarkably similar to that caused by the Rho inhibitor, C3 exoenzyme, in HeLa cells (30) suggesting that these morphological changes were due to inhibition of Rho proteins. Consistent observation was obtained form both HCC cell lines SMMC-7721 and BEL7402 as well as fibroblast cell lines Swiss-3T3 and Rat6 suggesting that the effects of DLC1 on actin-stress fiber formation and cell morphological changes were not cell line specific response.
In silico analysis had revealed that several lysine and arginine residues are highly conserved in various mammalian RhoGAPs. A previous study on the rat p122RhoGAP (DLC1 ortholog) has provided evidence that Lys-706 residue is involved in stimulating the GTP hydrolysis of active GTP-bound Rho proteins (13) . To further confirm the RhoGAP function of DLC1, we constructed a RhoGAP deficient mutant by converting the Lys-714 into glutamate (K714E), which corresponds to the Lys-706 in rat p122RhoGAP. Expression of DLC1-K714E mutant abolished the DLC1 induced cell rounding and cortical retraction. In addition, upon LPA induction, DLC1-K714E mutant expressing cells formed actin stress fibers as efficiently as the empty vector control ( Figure 4B ). Similar findings were also reproduced in another DLC1 null HCC cell line (BEL7402) as well as in fibroblast cell lines (Swiss-3T3 and Rat 6) (data not shown). Taken together, our results strongly suggest that DLC1 functions as a RhoGAP and negatively regulates the activity of Rho proteins in vivo.
RhoGAP activity was essential for DLC1 mediated tumor suppressor function
We hypothesized that DLC1 suppressed cancer cell growth through negatively regulating the activity of Rho proteins. In order to test this hypothesis, colony suppression assays were performed on SMMC-7721 cells transfected with wild-type and RhoGAP deficient mutant DLC1. We found that ectopic overexpression of wild-type DLC1 significantly suppressed the colony formation in HCC cells ( Figure 5A ). Indeed, this finding was highly consistent with that found in cancer cell lines of different tissue types as reported by us and others (26, 31, 32) . In contrast to wild-type DLC1, expression of the RhoGAP-deficient mutant had no effect on the colony formation ability of SMMC-7721 cells. The number of colony formed by DLC1-K714E
transfected cells was comparable to that of the empty vector ( Figure 5A ). Thus, our data suggest that the RhoGAP activity is essential for DLC1 mediated tumor suppressor function and lend further support to the notion that DLC1 exerts tumor suppressor function by negatively regulating the activity of Rho proteins.
Cooperation among the multi-functional domains of DLC1 was required for its growth inhibition of HCC cells
DLC1 contains three conserved functional domains. Apart from the RhoGAP domain, SAM
and START domains are located at the N-terminal and C-terminal of the DLC1 protein, respectively ( Figure 4A ). We have demonstrated in this study that the RhoGAP domain of DLC1 is essential for negative regulation of Rho activity and suppression of cancer cell growth.
However, the roles of the SAM and START domains in DLC1 functions are largely unclear.
To address this question, we expressed different truncated DLC1 cDNAs in SMMC-7721 cells ( Figure 4A ). The expression of the truncated DLC1 proteins was confirmed by western blotting using anti-Myc antibody ( Figure 5B ). The RhoGAP activity and tumor suppressor function of these truncated constructs were determined by their ability to inhibit Rho mediated actin stress fiber formation ( Figure 4B ) and to suppress colony formation ( Figure 5A Figure 4A ). Similar results were also obtained when these experiments were performed in BEL7402 and Rat 6 cell lines, indicating that these findings were not merely due to a cell line specific phenotype (data not shown).
Discussion
DLC1 is a candidate tumor suppressor gene recently isolated from PCR-based subtractive hybridization in human HCC (8). Follow-up studies indicate that inactivation of DLC1 is implicated in hepatocarcinogenesis (14, 26, 33, 34) . Although somatic mutations in DLC1 gene are rare (14, 35, 36) , loss of heterozygosity is present in approximately half of primary HCCs (8, 14, 35) . DLC1 mRNA expression is significantly down-regulated in primary HCC samples (14, 26) . Earlier in vitro studies using hepatoma cell lines not expressing DLC1 have revealed that epigenetic alterations, including promoter methylation, are also responsible for DLC1 silencing in HCC (14, 34) . In addition, methylation of the DLC1 promoter was detected in about 24% of primary HCC samples (14) . These findings suggest that epigenetic silencing of DLC1 is not merely an artifact introduced by in vitro tissue culture but may substantially contribute to human carcinogenesis (14) . The frequent inactivation of the DLC1 gene in HCC prompted us to further investigate its tumor suppressor functions. We previously showed that transfection of DLC1 cDNA into HCC cell lines resulted in inhibition of colony formation (26) .
Recently, inactivation of the DLC1 gene has also been observed in human breast, gastric and lung cancers (31, 32, 37, 38) , suggesting that DLC1 functions as a bona fide tumor suppressor Our previous in vitro study indicated that DLC1 negatively regulated the activity of Rho family proteins by promoting the GTP hydrolysis (14) . In the present study, we further demonstrated 20 that DLC1 expression could significantly suppress Rho-dependent actin stress fibers formation in HCC and fibroblast cell lines. Thus, our findings strongly imply that overexpression of DLC1 can inhibit the activity of Rho proteins and further support the notion that DLC1 functions as RhoGAP in vivo.
Cell motility is tightly regulated by the activity of Rho proteins through actin cytoskeletal rearrangements (29) . Recently, a growing body of evidence has suggested that deregulation of Rho proteins are implicated in cancer cell invasion and metastasis. For instance, overexpression of wild-type RhoA in rat hepatoma cells induced cell invasion in both in vitro and in vivo conditions (39) . On the other hand, dominant negative RhoA (RhoA N19) was sufficient to inhibit the invasiveness of human prostate cancer cells (40) . It has also been documented that RhoA specific inhibitor C3 exoenzyme greatly suppressed the cell motility of HCC cell lines, Li7 and KYN-2. In sharp contrast, the cell motility of these cell lines was strongly induced by LPA treatment (41) . Based on the above evidence, we hypothesize that DLC1, a negative regulator of Rho proteins, will reduce cell motility. Indeed, our data clearly showed that expression of DLC1 significantly inhibited cell motility and invasiveness of HCC cells.
More than 30 potential down-stream effectors of Rho family proteins have been identified (42) .
These effectors may be responsible for the different specific cellular functions mediated by the Rho proteins. ROCK is one of the best characterized down-stream effectors which selectively binds to active GTP bound Rho proteins and regulates cell cytoskeletal reorganization through phosphorylating a wide range of cytoskeletal proteins (43, 44) . Recent studies indicated that deregulation of Rho/ROCK signaling pathway is responsible for cancer invasion and metastasis (22, 41, 45) . It is tempting to speculate that DLC1 suppresses cell motility and Thus, we propose that both the RhoGAP and START domains and an unidentified domain located within the region of 292-638 amino acid residues are required for DLC1-mediated growth and stress fiber inhibition, and further investigations are warranted in this regard.
Furthermore, similar with the RhoGAP deficient mutant, we noticed a close association between RhoGAP activity and tumor suppressor function of various truncated DLC1 cDNAs.
Thus our results suggest that DLC1 tumor suppressor function are related to its Rho protein inhibitory activity.
In conclusion, our findings thus far have indicated that DLC1 significantly inhibited Rho-mediated actin stress fiber formation, and the RhoGAP activity of DLC1 was essential for tumor suppressor function. Expression of DLC1 suppressed cell proliferation, anchorage-independent growth, tumorigenicity and invasiveness of HCC cells. Expression of DLC1 significantly inhibited cell motility of SMMC-7721 (P < 0.001, t-test).
